Tricida Phase III VALOR-CKD clinical failure, share price plummets 94%
ADC评论
October 25, 2022
On October 24, Tricida announced key results from the Phase III VALOR-CKD clinical trial, which was designed to evaluate the ability of veverimer to slow
